[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628775":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":42,"collaborators":26,"id":46,"slug":26,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":26,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":26,"maxAge":26,"enrollmentInfo":53,"targetDuration":26,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":64,"whyStopped":26,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":26},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Daily tadalafil 5 mg user","ACTIVE_COMPARATOR","Patients will have daily tadalafil 5 mg for 3 months post AEEP",[13],"Drug: Tadalafil 5mg (Male)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Omiga 3 for patient",[19],"Drug: Omiga 3",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tadalafil 5mg (Male)","Tadalafil 5 mg is a phosphodiesterase type 5 (PDE-5) inhibitor taken orally, commonly prescribed as a once-daily low dose therapy. It works by relaxing smooth muscle and improving blood flow in specific tissues.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Omiga 3","Giving omiga 3 for patients who are not in tadalafil group",[15],[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Ali adel Mansour Hageb, GP","CONTACT","+201109049717","+967781118703","Alihajeb42@gmail.com",{"name":39,"role":34,"phone":40,"phoneExt":26,"email":41},"Adel Kurkar Abdallah, Prof Dr","+201098197880","kurkar1970@gmail.com",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Ali Adel Mansour Hageb","Dr","100628775",false,"NCT07466030","Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate","Impact of Daily Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate :A Randomized , Single Blinded ,Controlled Trial\"","Inclusion Criteria:\n\n* Must be able to swallow tablets\n* Adult males undergoing elective AEEP for symptomatic benign prostatic hyperplasia (BPH) with prostate volume ≥40 ml , Moderate to severe LUTS defined by International Prostate Symptom Score (IPSS) ≥19 at baseline.\n* Patient is Willing to participate and able to provide written informed consent\n\nExclusion Criteria:\n\n* Contraindications to tadalafil (e.g., nitrate use, severe hepatic\u002Frenal impairment, uncontrolled hypotension) , neurogenic bladder. , Preoperative urinary catheter dependence , post-void residual urine \\>350 ml. ,, Cognitive impairment precluding questionnaire completion","MALE",{"count":54,"type":55},40,"ESTIMATED","INTERVENTIONAL",[58],"PHASE1","The aim of this study is to evaluate the impact of daily tadalafil 5 mg on storage lower urinary tract symptoms (LUTS) during the early postoperative period following Anatomical endoscopic enucleation of prostate in a randomized controlled clinical trial.",[61],"BPH (Benign Prostatic Hyperplasia)",[63],"Storage LUTS post AEEP","NOT_YET_RECRUITING","2026-03-07",{"date":67,"type":68},"2026-03-12","ACTUAL",{"date":70,"type":55},"2026-03-01",{"date":72,"type":55},"2028-09-01",{"name":5,"class":6}]